GlassScriptPhysician profile
Joseph Marzano
NPI 1427052133
$6,278.64
in general payments reported to CMS, 2019-2025
37 companies · $1,484 in 2025
The $1,484 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,206 · 2020: $411 · 2021: $115 · 2022: $848 · 2023: $1,097 · 2024: $1,117 · 2025: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,688 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,688.48 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,009.31 | 2019-2025 | |
| Janssen Biotech, INC. | $1,020.62 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $527.31 | 2019-2025 | Xifaxan |
| Pfizer INC. | $497.22 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $293.06 | 2022-2024 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $224.73 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $169.47 | 2019-2025 | Epclusa |
| Intercept Pharmaceuticals, INC. | $168.54 | 2019-2023 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $157.84 | 2023-2024 | Zeposia, Cobenfy |
| Lilly USA, LLC | $136.70 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $126.73 | 2019-2022 | |
| Qol Medical, LLC | $123.91 | 2019-2023 | Sucraid |
| Celgene Corporation | $112.74 | 2023-2024 | Zeposia |
| Genzyme Corporation | $98.30 | 2023-2025 | |
| Ucb, INC. | $63.22 | 2019-2020 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Marzano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.